N THE UNITED STATES PATENT AND TRADEMARK OFFICE

classification is Application: Subclass _

Prior Application:

Exam'r: Gary L. Kunz, Ph.D. Group Art Unit: 1803 Attorney's Docket No.: Enz-47 (C2)

FILED BY EXPRESS MAIL

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231 BOX FWC (if under §1.62)

Sir:

This is a request for filing a X CONTINUATION DIVISIONAL
CONTINUATION-IN-PART application under X 37 CFR §1.60
37 CFR §1.62, of pending prior application Serial No. 07/446,235
37 CFR §1.62, of pending prior application Serial No. 07/446,239 filed on December 4, 1989 of Christine L. Brakel et al.
Inventor(s)

for:

- 00

MODIFIED NUCLEOTIDE COMPOUNDS

Title of Invention

1.		Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy.
2.		A copy of the verified statement under 37 CFR §1.9 and §1.27 establishing small entity status in the prior application is also enclosed. Small entity status is still applicable.
3.	X	The filing fee is calculated as follows:

CLĄIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT									
					RATE			FEE	
	Number Filed		Number Extra		Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	1	=	0	x	\$ 11	\$22	=	\$	\$0
Independent Claims	1.	=	0	x	\$ 38	\$76	H	\$	\$0
Multiple Dependent Claims Presented:Yes _x No					\$115	\$230		\$	\$
No. 457, 00000089 Day: 051135 If the difference in Col. 1984 1993 9 than zero, e 385, 00 CH			nter "C	o" in Col.2	BASIC FEE		\$ 365	\$0	
						TOTAL FEE		\$635	\$0

Attorney's Docket No. Enz-47(C2)

C:\wpwin\ENZ.47\C2\rqstfor.con

EXPRESS	MAIL CERTIFICATE
"Express Mail" Label	No. TB842440643

Deposit Date

JUNE 7, 1995

Deposit Date

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patenty and Tenderiarks, Washington DC 20231

June 7, 1495

Ronald C. Fedus Reg. No. 32,567

Date

	Serial Filed:		Not Yet Assigned Herewith	
	Page:		(Request for a Continuation Application Under 37 C.F.R. § 1.60 - June 7, 1995)	
	4.	_x_	The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A duplicate copy of this sheet is enclosed.	
		X	Any additional filing fees required under 37 CFR §1.16.	
		X	Any patent application processing fees under 37 CFR §1.17.	
•	5.	X_	The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. <u>05-1135</u> . A duplicate copy of this sheet is enclosed.	
,			X Any patent application processing fees under 37 CFR §1.17. The issue fee set in 37 CFR §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR §1.311(b). X Any filing fees under 37 CFR §1.16 for presentation of extra claims.	
	6.		A check in the amount of \$ is enclosed.	
	7.		Cancel claims	
	8.	X	Amend the specification by inserting before the first line of the sentence: This is a X continuation, divisional, _	
D1			continuation-in-part, of application Serial No. 07/446,235 filed on December 4, 1989	
	9.	X	Transfer the drawings from the prior application.	
	10.		Informal Formal drawings are enclosed.	
	11.	<u>X</u>	Abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.	
	12.		Priority of application Serial No filed on is claimed under 35 U.S.C. §119 The certified copy of the priority application has been filed in prior application Serial No, filed	
	13.	<u>.</u> x	The prior application is assigned of record to Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc. 575 Fifth Avenue, New York, New York 10017.	
	14.		A preliminary amendment is enclosed.	

Brakel et al.

Serial Filed:		Not Yet Assigned Herewith (Provent for a Continuation Application Hadas 27 C.F.B., § 1.60)
Page:	3	(Request for a Continuation Application Under 37 C.F.R. § 1.60 - June 7, 1995)
15.	X	The power of attorney in the prior application is to: Ronald C. Fedus, Reg. No. 32,567.
		(a) The power appears in the original papers in the prior application.
		(b) X Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
		(c) A copy of a new substitute power of attorney is enclosed.
	,	(d) X Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)
		Ronald C. Fedus, Esq. Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. 575 Fifth Avenue (18th Floor) New York, New York 10017
16.	X	Also accompanying this Request is a Petition to Revive An Unintentionally Abandoned Application Under 37 C.F.R. §1.137(b).
17.		I hereby verify that the attached papers are a true copy of prior application Serial No.
18.	X·_	As noted under No. 16 above, this Request For a Continuation Application is accompanying the Petition to Revive an Unintentionally abandoned Application Under 37 C.F.R. § 1.137(b), along with the requisite petition fee therefor. With the expected granting of the Petition, (if such petition is necessary) the parent application will be copending with the filing of this new

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

continuation application.

Brakel et al.

Brakel et al.

Serial No.: Not Yet Assigned

Filed:

Herewith

Page: 4

(Request for a Continuation Application Under 37 C.F.R. § 1.60 -

June 7, 1995)

Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

June 7, 1995 Date

Signature [Ronald C. Fedus] Registration No. 32, 567

Attorney for Applicants ___ Inventor(s)

Assignee of Complete Interest X Attorney or Agent of Record

___ Filed under 37 CFR §1.34(a)

Address of Signator: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. 575 Fifth Avenue (18th Floor) New York, New York 10017